Mitsubishi Tanabe Pharma News Release

June 18, 2021

Launch of TENELIA® OD Tablet for Type 2 Diabetes Mellitus
Toward further convenience and improvement of Medication Compliance of DPP-4 inhibitors

Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office: Chuo-ku, Osaka; President & Representative Director: Hiroaki Ueno) today announced that MTPC launched the selective DPP-4 inhibitor TENELIA® OD Tablets 20mg and 40mg (TENELIA® OD Tablets, generic name: Teneligliptin hydrobromide hydrate tablet) in Japan on June 18, 2021, following today's inclusion of TENELIA® OD Tablets in the National Health Insurance drug price list.

MTPC has developed orally disintegrating tablets (OD tablets) with the aim of further improving convenience and compliance for elderly patients, patients with impaired swallowing function, and patients who require restricted fluid intake. In February 2021, MTPC has received manufacturing and marketing approval for TENELIA® OD tablets, the first OD tablet of DPP-4 inhibitor in Japan.

TENELIA® 20mg tablets and TENELIA® 40mg tablets were approved in June 2012 and August 2018, respectively, for use in patients with type 2 diabetes mellitus.

Through TENELIA® OD Tablets, MTPC will offer new options for the treatment of type 2 diabetes and contribute even further to the treatment of diabetes.

Mitsubishi Tanabe Pharma Corporation
Communication Crossroads Department
Media contacts: TEL:+81 6 6205 5119

Product Name	TENELIA® OD Tablet 20mg/ TENELIA® OD Tablet 40mg
JAN	Teneligliptin Hydrobromide Hydrate
Indication	Type 2 Diabetes Mellitus
Dosage	once daily, starting dose is 20mg, and maximum dose is 40 mg.
Packaging	20mg 100tablets［10tablets（PTP）×10］ 40mg 100tablets［10tablets（PTP）×10］
NHI Price	134.70 yen / 20mg tablet 202.50 yen / 40mg tablet
Approval (Japan)	February 5,2021
NHI price listing	June 18, 2021
Release (Japan)	June 18, 2021
Manufacturer and Marketer	Mitsubishi Tanabe Pharma Corporation
Co-Marketer	Daiichi Sankyo Co., Ltd.